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A randomized trial of 7-day doripenem versus
10-day imipenem-cilastatin for ventilator-
associated pneumonia
Marin H Kollef1*, Jean Chastre2, Marc Clavel3, Marcos I Restrepo4, Bart Michiels5, Koné Kaniga6, Iolanda Cirillo6,
Holly Kimko6 and Rebecca Redman6
Abstract
Introduction: The aim of this study was to compare a 7-day course of doripenem to a 10-day course of
imipenem-cilastatin for ventilator-associated pneumonia (VAP) due to Gram-negative bacteria.
Methods: This was a prospective, double-blinded, randomized trial comparing a fixed 7-day course of doripenem
one gram as a four-hour infusion every eight hours with a fixed 10-day course of imipenem-cilastatin one gram as
a one-hour infusion every eight hours (April 2008 through June 2011).
Results: The study was stopped prematurely at the recommendation of the Independent Data Monitoring
Committee that was blinded to treatment arm assignment and performed a scheduled review of data which
showed signals that were close to the pre-specified stopping limits. The final analyses included 274 randomized
patients. The clinical cure rate at the end of therapy (EOT) in the microbiological intent-to-treat (MITT) population
was numerically lower for patients in the doripenem arm compared to the imipenem-cilastatin arm (45.6% versus
56.8%; 95% CI, -26.3% to 3.8%). Similarly, the clinical cure rate at EOT was numerically lower for patients with
Pseudomonas aeruginosa VAP, the most common Gram-negative pathogen, in the doripenem arm compared to
the imipenem-cilastatin arm (41.2% versus 60.0%; 95% CI, -57.2 to 19.5). All cause 28-day mortality in the MITT
group was numerically greater for patients in the doripenem arm compared to the imipenem-cilastatin arm (21.5%
versus 14.8%; 95% CI, -5.0 to 18.5) and for patients with P. aeruginosa VAP (35.3% versus 0.0%; 95% CI, 12.6 to 58.0).
Conclusions: Among patients with microbiologically confirmed late-onset VAP, a fixed 7-day course of doripenem
was found to have non-significant higher rates of clinical failure and mortality compared to a fixed 10-day course
of imipenem-cilastatin. Consideration should be given to treating patients with VAP for more than seven days to
optimize clinical outcome.
Trial Registration: ClinicalTrials.gov: NCT00589693
Introduction
Ventilator-associated pneumonia (VAP) is the most com-
mon infection identified in critically ill patients, often due
to high risk pathogens, such as Pseudomonas aeruginosa
and Acinetobacter baummannii, and accounts for most of
the antibiotic utilization within intensive care units (ICUs)
[1,2]. Several guidelines have been published giving
recommendations for the treatment of VAP, including the
total duration of therapy [3,4]. Unfortunately, the evidence
supporting an optimal duration of antibiotic therapy for
VAP is limited and primarily based on the results of a sin-
gle randomized trial [5]. A recent meta-analysis found that
for patients with nosocomial pneumonia not due to non-
lactose fermenting Gram-negative bacteria (NLFGNB), a
short fixed-course (7 or 8 days) of antibiotic therapy may
be more appropriate than a prolonged course (10 to 15
days) in terms of reducing the subsequent emergence of
antibiotic-resistant pathogens [6]. However, the concern
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with using short durations of antibiotic therapy is treat-
ment failure and potentially adverse outcomes.
Carbapenems are bactericidal against Gram-negative
pathogens that commonly cause VAP, including P. aerugi-
nosa, A. baumannii and extended-spectrum beta-lacta-
mase (ESBL) producing enteric bacteria, and are,
therefore, recommended for initial empiric therapy for
VAP in patients with late-onset disease or individuals with
risk factors for infection with multidrug-resistant (MDR)
pathogens [3,4,7]. Doripenem 500 mg was shown to be
non-inferior to comparator agents in two previous rando-
mized controlled studies in patients with hospital-acquired
pneumonia, including VAP, when administered for 7 to 14
days, with the length of therapy guided by the patient’s
condition and at the discretion of the treating physicians
[8,9]. In addition, pharmacokinetic/pharmacodynamic
(PK/PD) modeling from data from other studies demon-
strated that one gram doses infused over four hours could
target pathogens with higher minimum inhibitory concen-
trations (MICs) and provide a more sustained duration of
free drug concentrations above the MIC of most Gram-
negative pathogens causing VAP (especially P. aeruginosa
and Acinetobacter spp.) than the 500 mg dose [10,11].
Therefore, we performed an investigation to compare the
administration of a higher 1 g dose of doripenem for a
fixed 7-day course to a fixed10-day course of imipenem-
cilastatin for the treatment of late-onset VAP. The ratio-
nale for the use of a 7-day course of doripenem was
guided by data from the prior doripenem nosocomial
pneumonia registration trials and a previous study demon-
strating similar outcomes in patients with VAP treated
with 8 and 15 days of antibiotic therapy [5,8,9].
Doripenem is not approved for treatment of nosocomial
pneumonia, including VAP, in the United States (US) but
is approved for use in adults with these infections in the
European Union and other countries outside of the US.
Materials and methods
Study design overview
A randomized, double-blind, multicenter study was per-
formed comparing the efficacy and safety of a fixed 7-day
regimen of doripenem to a fixed 10-day regimen of imipe-
nem-cilastatin in patients with late-onset VAP, with
patients enrolled between 1 April 2008 and 17 May 2011.
Ventilated patients were stratified at the time of randomi-
zation based on age (≤65 years or >65 years), degree of
lung injury as measured by the ratio of the partial pressure
of arterial oxygen/fraction of inspired oxygen (PaO2/FiO2
of ≤250 or >250), and geographic region (Western Europe,
North America, Australia; Central and South America; or
Eastern Europe and Asia). The institutional review board
at each site (see Acknowledgements) approved the proto-
col, and all patients or their authorized representatives
provided written informed consent (NCT00589693). (See
Additional file 1 for complete Methods section).
Randomization and treatment regimens
In this double-blinded study patients were randomized
(1:1) to receive either a fixed 7-day course of doripenem
one gram as a four-hour infusion every eight hours or a
fixed 10-day course of imipenem-cilastatin one gram as a
one-hour infusion every eight hours. Treatment was ran-
domized with use of a central interactive phone system.
Randomization was not stratified by study site. Patients
randomized to doripenem treatment received in parallel 7
days of active therapy and 10 days of placebo. Patients ran-
domized to imipenem-cilastatin treatment received in par-
allel 10 days of active therapy and 7 days of placebo. All
patients received active study drug and placebo infusions
on Days 1 through 7. Patients randomized to imipenem-
cilastatin continued to receive active study drug on Days
8, 9 and 10 and patients randomized to doripenem
received placebo. A switch to oral antibacterial therapy
was not allowed. Adjunctive therapy was allowed at the
discretion of the treating physician with vancomycin
(1 gram every 12 hours) or linezolid (600 mg every 12
hours) directed at methicillin-resistant Staphylococcus aur-
eus (MRSA) and amikacin (15 mg/kg once daily) for
patients at risk for infection with a carbapenem-resistant
Gram-negative pathogen.
Outcomes and follow-up
The intent-to-treat (ITT) population was defined as all
patients who received at least one dose of the study drug.
The microbiological ITT (MITT) population was the sub-
set of the ITT population who had at least one Gram-
negative pathogen identified on bronchoalveolar lavage
(BAL) or mini-BAL at a density >104 CFU/mL with an
imipenem MIC <8 μg/mL. Patients were included in the
MITT population if they had a second pathogen isolated
from BAL/mini-BAL at a density >104 CFU/mL with an
imipenem MIC >8 μg/mL. This was allowed to optimize
enrollment of patients with eligible Gram-negative patho-
gens and to allow inclusion of co-infection with MRSA.
However, patients who only grew pneumonia pathogens
with imipenem MICs >8 μg/mL, such as MRSA or Steno-
trophomonas maltophilia, were excluded from the MITT
population.
Clinical assessments were performed at baseline and at
the end of therapy (EOT), defined as Day 10 for both
groups, or within 24 hours after the last dose of blinded
study drug therapy if discontinued early. Laboratory
assessments were performed at baseline, Day 7 and EOT.
Follow-up assessments were conducted 7 to 14 days and
28 to 35 days after EOT. The primary endpoint of this
study was clinical cure at EOT (Day 10) in the MITT
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population. Secondary endpoints included 28-day all-
cause mortality in the MITT populations and clinical cure
in the subgroup having P. aeruginosa identified as a quali-
fying pathogen.
Clinical cure was defined as improvement or lack of
progression of baseline radiographic findings at EOT and
resolution of signs and symptoms of pneumonia at fol-
low-up. Failure was defined as persistence or progression
of signs and symptoms or progression of radiological
signs of pneumonia at EOT; termination of study medi-
cations due to “lack of efficacy"; administration of any
systemically absorbed or aerosolized antibiotic for any
reason; death from any cause; an indeterminate response;
or relapsed infection at follow-up after termination of
study medications. Adverse events (AEs) including mor-
tality, vital signs and laboratory parameters were also
evaluated.
Statistical analysis
The initial sample size calculation was based on assump-
tions from a previous Phase 3 doripenem pneumonia
study conducted in patients with VAP [9). Assuming a
clinical cure rate of 60% in both treatment arms and using
a non-inferiority margin of 15% and a one-tailed 2.5% sig-
nificance level, a sample size of 168 per treatment arm
would have a power of 80% to establish non-inferiority. If
one further assumed that only 70% of the patients would
qualify for inclusion in the MITT analysis set, then the
sample size required would be 240 per treatment arm for
a total of 480 patients. Categorical data were expressed as
frequency distributions and the difference between groups
was assessed by using the normal approximation to the
difference between two binomial proportions. All confi-
dence intervals were two-tailed and a P-value <0.05 repre-
sented statistical significance. No correction for multiple
comparisons was implemented. The P-values in the sec-
ondary and subgroup analyses are nominal in nature, and
not inferential.
Independent Data Monitoring Committee
An Independent Data Monitoring Committee (IDMC) was
established to evaluate data related to efficacy and safety at
predefined time points (see on-line supplement for IDMC
statistical monitoring guidelines). At their last meeting, the
IDMC reviewed available data from approximately half the
total number of patients targeted for enrollment and
recommended that the enrollment be terminated because
of inferior efficacy and higher mortality in one of the treat-
ment arms. Therefore, the analyses were based on data
from the 274 subjects who had been randomized into the
study at the time enrollment was terminated. In addition,
five sites (three in Guatemala, one in Germany, one in the
United States) that enrolled a total of 41 patients were
deemed to be non-compliant with good clinical practices
(GCP) prior to database lock and were excluded from the
primary analyses of efficacy and safety (Figure 1). How-
ever, to assess the robustness of the primary efficacy and
safety conclusions, sensitivity analyses were performed by
including patients from these five sites. These sensitivity
analyses support the primary efficacy and safety
conclusions.
Results
Patient disposition and characteristics
There were 274 randomized patients prior to stopping the
study. In addition to the 41 patients from the GCP non-
compliant sites, 7 patients were excluded who never
received the study drug (1 patient was excluded for meet-
ing both of these criteria). The ITT group comprised 227
patients (doripenem, n = 115; imipenem-cilastatin, n =
112) and the MITT group comprised 167 patients (doripe-
nem, n = 79; imipenem-cilastatin, n = 88) (Figure 1).
Patient baseline characteristics were generally balanced
between treatment groups for the ITT and MITT popula-
tions although there were some differences between treat-
ment groups suggesting subjects in the doripenem arm
may have more severe illness. The majority of patients
were male, white, <65 years of age (mean of 54.1 years in
the MITT population), had an Acute Physiology and
Chronic Health Evaluation (APACHE) II score >15, a clin-
ical pulmonary infection score (CPIS) ≥6, PaO2/FiO2 <250,
a creatinine clearance >50 ml/min, received >72 hours of
prior antibiotic therapy, and enrolled from sites in Europe
(Tables 1 and 2). The most common reasons patients in
the MITT population were admitted to the hospital were
for surgery (38.9%), including neurologic surgery (17.4%),
a neurologic event (20.4%) and trauma (18.6%). A qualify-
ing Gram-negative pathogen was isolated from 89.2% of
patients in the MITT population and more than half of
these patients had a second pathogen isolated from the
baseline BAL/mini-BAL at a density >104 CFU/mL.
The median duration of study drug therapy (including
placebo) was 9.7 days for each treatment arm in the MITT
population. The median duration of active study drug
therapy (excluding placebo) was 7.0 days in the doripenem
arm and 10.0 days in the imipenem-cilastatin arm for the
MITT population. Similar numbers of patients received
empiric adjunctive therapy with an aminoglycoside or an
anti-MRSA drug and less than 10% in both the ITT and
MITT groups continued adjunctive antibiotics beyond 72
hours after a carbapenem-resistant pathogen (defined as
imipenem MIC >8 μg/mL) was isolated (Tables 1 and 2).
Clinical and microbiologic response
The clinical cure rate at the EOT visit in patients in the
MITT group randomized to doripenem was lower than
the clinical cure rate in patients randomized to imipe-
nem-cilastatin (45.6% versus 56.8%; 95% CI, -26.3% to
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3.8%). Thus, non-inferiority of a fixed 7-day treatment
regimen with doripenem compared to a fixed 10-day
treatment regimen of imipenem-cilastatin was not
demonstrated at the 15% margin. Response differences
of 10% to 15% favoring imipenem-cilastatin remained
present in most subgroups (Figure 2), especially among
male patients and those with supra-normal creatinine
clearance. However, the larger differences in cure rates
in patients with supra-normal creatinine clearance
appear to be driven by the unusually high cure rates
among subjects in the imipenem-cilastatin arm with
creatinine clearance >150 ml/min (71.4%) compared to
cure rates among those with creatinine clearance >80 to
<150 ml/min (51.4%) and >50 to <80 ml/min (50.0%).
The mean CPIS values for MITT patients in both
treatment arms for study Days 1 through 11 is shown in
Figure 3. CPIS scores were similar for patients in the
doripenem arm and the imipenem-cilastatin arm for the
first eight days of the study. However, the CPIS scores
separated after Day 8 with the doripenem arm scores
remaining stable while the imipenem-cilastatin arm
scores continued to decrease.
The distribution of qualifying Gram-negative pathogens
that were pre-defined as being of specific interest (P. aeru-
ginosa, Acinetobacter spp., and Enterobacteriaceae) is
shown in Table 3. A larger proportion of patients in the
doripenem arm than the imipenem-cilastatin arm had
pneumonia due to P. aeruginosa (21.5% versus 11.4%) and
Acinetobacter spp. (19.0% versus 11.4%). The clinical cure
rate for the P. aeruginosa subgroup at EOT was numeri-
cally lower for subjects in the doripenem arm compared
to the imipenem-cilastatin arm (41.2% (7/17) versus 60.0%
(6/10); 95% CI, -57.2% to 19.5%). Cure rates were also
lower for patients in the doripenem arm infected with Aci-
netobacter spp. (40.0% (6/15) versus 50.0% (5/10); 95% CI:
-49.7% to 29.7%) and Enterobacteriaceae (53.5% (23/43)
versus 59.2% (29/49); 95% CI: -26.0% to 14.6%). Table 4
shows that the baseline characteristics for the P. aerugi-
nosa subgroup were similar between treatment arms.
The number of patients with pathogens at each MIC
was too small to draw definitive conclusions regarding
clinical cure rate by infecting pathogen MIC; however, for
the NLFGNB P. aeruginosa and A. baumannii, cure rates
and mortality for patients in either treatment arm did not
appear to increase with increasing MIC of the study drug
received suggesting conditions other than MIC played a
role in outcome (see Additional file 1, Table S1).
Safety
In the ITT population, the most frequently reported
adverse events in both treatment groups were anemia
(21.7% doripenem, 22.3% imipenem-cilastatin); urinary
tract infection (13.0% doripenem, 14.3% imipenem-
cilastatin); decubitus ulcer (12.2% doripenem, 9.8%
Figure 1 Patients enrolled and analyzed. ITT, intention-to-treat; MITT, Microbiological intention-to-treat. *Prior to study termination the
Marketing Authorization Holder for the study identified five study sites (three in Guatemala, one in Germany, one in the United States),
following independent internal reviews and re-monitoring by a contract research organization (CRO), that were found not to have adhered to
the study protocols, or the study logs could not verify protocol adherence, and thus their data were excluded from the primary analyses.
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Table 1 Baseline demographics - ITT analysis set
Doripenem Imipenem Total
(N = 115) (N = 112) (N = 227)
Sex, n (%)
N 115 112 227
Male 72 (62.6) 75 (67.0) 147 (64.8)
Female 43 (37.4) 37 (33.0) 80 (35.2)
Weight (kg)
N 115 112 227
Mean (SD) 75.6 (16.95) 79.8 (19.07) 77.7 (18.11)
Median 74.0 77.5 75.0
Range (45;150) (47; 170) (45; 170)
Height (cm)
N 114 110 224
Mean (SD) 169.5 (10.66) 171.3 (9.20) 170.3 (9.99)
Median 170.0 170.0 170.0
Range (140; 193) (150; 200) (140; 200)
Age (Years)
N 115 112 227
Mean (SD) 57.5 (16.53) 54.6 (18.46) 56.1 (17.53)
Median 58.0 58.0 58.0
Range (19; 89) (18; 88) (18; 89)
Race, n (%)
N 115 112 227
White 96 (83.5) 97 (86.6) 193 (85.0)
Black or African American 6 (5.2) 6 (5.4) 12 (5.3)
Asian 4 (3.5) 1 (0.9) 5 (2.2)
Other 9 (7.8) 8 (7.1) 17 (7.5)
Region, n (%)
N 115 112 227
Central and South America 24 (20.9) 24 (21.4) 48 (21.1)
Eastern Europe and Asia 34 (29.6) 33 (29.5) 67 (29.5)
Western Europe, North America, Australia 57 (49.6) 55 (49.1) 112 (49.3)
APACHE II score, n (%)
N 115 112 227
≤15 48 (41.7) 49 (43.8) 97 (42.7)
16 to 19 30 (26.1) 34 (30.4) 64 (28.2)
≥20 37 (32.2) 29 (25.9) 66 (29.1)
CPIS, n (%)
N 115 112 227
Missing 3 (2.6) 2 (1.8) 5 (2.2)
<6 8 (7.0) 5 (4.5) 13 (5.7)
6 to 7 64 (55.7) 64 (57.1) 128 (56.4)
8 to 9 30 (26.1) 34 (30.4) 64 (28.2)
>9 10 (8.7) 7 (6.3) 17 (7.5)
SOFA Score
N 57 58 115
Mean (SD) 6.0 (2.70) 5.5 (2.39) 5.8 (2.55)
Median 6.0 5.0 5.0
Range (0; 14) (2; 12) (0; 14)
Charlson Comorbidity Index
N 114 112 226
Mean (SD) 3.0 (2.72) 2.8 (2.45) 2.9 (2.59)
Kollef et al. Critical Care 2012, 16:R218
http://ccforum.com/content/16/6/R218
Page 5 of 17
imipenem-cilastatin); hypokalemia (10.4% doripenem,
10.7% imipenem-cilastatin); diarrhea (9.6% doripenem,
11.6% imipenem-cilastatin); and hypotension (9.6%
doripenem, 8.9% imipenem-cilastatin). Clinically
important adverse events (all-causality) are shown in
Additional file 1. Laboratory results were also compar-
able between the study arms (see Additional file 1,
Table S2).
Table 1 Baseline demographics - ITT analysis set (Continued)
Median 3.0 3.0 3.0
Range (0; 14) (0; 9) (0; 14)
PaO2/FiO2, n (%)
N 115 112 227
≤250 67 (58.3) 61 (54.5) 128 (56.4)
>250 48 (41.7) 51 (45.5) 99 (43.6)
Bacteremia, n (%)
N 115 112 227
No 109 (94.8) 107 (95.5) 216 (95.2)
Yes 6 (5.2) 5 (4.5) 11 (4.8)
Creatinine clearance, n (%)
N 115 112 227
Supra normal (≥150 ml/min) 23 (20.0) 34 (30.4) 57 (25.1)
Normal (≥80 to <150 ml/min) 46 (40.0) 44 (39.3) 90 (39.6)
Mild renal failure (>50 to <80 ml/min) 33 (28.7) 26 (23.2) 59 (26.0)
Moderate renal failure (>30 to ≤50 ml/min) 7 (6.1) 4 (3.6) 11 (4.8)
Severe renal failure (≤30 ml/min) 6 (5.2) 4 (3.6) 10 (4.4)
Failed antibiotic treatment for VAP, n (%)
N 69 78 147
No 59 (85.5) 67 (85.9) 126 (85.7)
Yes 10 (14.5) 11 (14.1) 21 (14.3)
Prior antibacterial therapy usage (hours), n (%)
N 115 112 227
<24 28 (24.3) 35 (31.3) 63 (27.8)
≥24 to <48 10 (8.7) 10 (8.9) 20 (8.8)
≥48 to ≤72 9 (7.8) 5 (4.5) 14 (6.2)
>72 68 (59.1) 62 (55.4) 130 (57.3)
Adjunctive therapy, n (%)
N 115 112 227
No 75 (65.2) 79 (70.5) 154 (67.8)
Yes
≤72 Hrs 32 (27.8) 25 (22.3) 57 (25.1)
>72 Hrs 8 (7.0) 8 (7.1) 16 (7.0)
Adjunctive aminoglycoside, n (%)
N 40 33 73
No 19 (47.5) 20 (60.6) 39 (53.4)
Yes
≤72 Hrs 20 (50.0) 12 (36.4) 32 (43.8)
>72 Hrs 1 (2.5) 1 (3.0) 2 (2.7)
Adjunctive vancomycin/linezolid, n (%)
N 40 33 73
No 14 (35.0) 9 (27.3) 23 (31.5)
Yes
≤72 hrs 20 (50.0) 18 (54.5) 38 (52.1)
>72 hrs 6 (15.0) 6 (18.2) 12 (16.4)
APACHE, Acute Physiology and Chronic Health Evaluation; CPIS, Clinical Pulmonary Infection Score; ITT, intention-to-treat; SOFA, Sequential Organ Failure
Assessment
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Table 2 Baseline demographics - MITT analysis set
Doripenem Imipenem Total
(N = 79) (N = 88) (N = 167)
Sex, n (%)
N 79 88 167
Male 48 (60.8) 61 (69.3) 109 (65.3)
Female 31 (39.2) 27 (30.7) 58 (34.7)
Weight (kg)
N 79 88 167
Mean (SD) 75.5 (17.85) 78.7 (15.66) 77.2 (16.75)
Median 75.0 78.0 76.0
Range (45; 150) (47; 143) (45; 150)
Height (cm)
N 79 87 166
Mean (SD) 170.8 (9.76) 171.7 (8.73) 171.3 (9.22)
Median 170.0 170.0 170.0
Range (148; 193) (150; 190) (148; 193)
Age (years)
N 79 88 167
Mean (SD) 54.9 (16.10) 53.4 (18.94) 54.1 (17.62)
Median 56.0 57.0 57.0
Range (19; 89) (18; 88) (18; 89)
Race, n (%)
N 79 88 167
White 65 (82.3) 75 (85.2) 140 (83.8)
Black or African American 5 (6.3) 6 (6.8) 11 (6.6)
Asian 1 (1.3) 1 (1.1) 2 (1.2)
Other 8 (10.1) 6 (6.8) 14 (8.4)
Region, n (%)
N 79 88 167
Central and South America 20 (25.3) 19 (21.6) 39 (23.4)
Eastern Europe and Asia 24 (30.4) 27 (30.7) 51 (30.5)
Western Europe, North America, Australia 35 (44.3) 42 (47.7) 77 (46.1)
APACHE II score group, n (%)
N 79 88 167
≤15 34 (43.0) 42 (47.7) 76 (45.5)
16 to 19 24 (30.4) 21 (23.9) 45 (26.9)
≥20 21 (26.6) 25 (28.4) 46 (27.5)
CPIS, n (%)
N 79 88 167
Missing 2 (2.5) 1 (1.1) 3 (1.8)
<6 4 (5.1) 2 (2.3) 6 (3.6)
6 to 7 43 (54.4) 50 (56.8) 93 (55.7)
8 to 9 23 (29.1) 29 (33.0) 52 (31.1)
>9 7 (8.9) 6 (6.8) 13 (7.8)
SOFA score
N 41 46 87
Mean (SD) 5.7 (2.53) 5.2 (2.24) 5.4 (2.38)
Median 6.0 5.0 5.0
Range (0; 11) (2; 12) (0; 12)
Charlson Comorbidity Index
N 79 88 167
Mean (SD) 2.4 (2.08) 2.8 (2.48) 2.6 (2.30)
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All-cause 28-day mortality in the MITT group was
numerically higher for patients in the doripenem arm
compared to the imipenem-cilastatin arm (21.5% (17/79)
doripenem, 14.8% (13/88) imipenem-cilastatin; 95% CI,
-5.0% to 18.5%) and greater for patients with P. aerugi-
nosa VAP (35.3% (6/17) versus 0.0% (0/10); 95% CI,
12.6% to 58.0%). Similar trends but smaller mortality
differences were demonstrated for the sensitivity
Table 2 Baseline demographics - MITT analysis set (Continued)
Median 3.0 2.0 3.0
Range (0; 9) (0; 9) (0; 9)
PaO2/FiO2, n (%)
N 79 88 167
≤250 50 (63.3) 51 (58.0) 101 (60.5)
>250 29 (36.7) 37 (42.0) 66 (39.5)
Bacteremia, n (%)
N 79 88 167
No 73 (92.4) 84 (95.5) 157 (94.0)
Yes 6 (7.6) 4 (4.5) 10 (6.0)
Creatinine Clearance, n (%)
N 79 88 167
Supra normal (≥150 ml/min) 18 (22.8) 28 (31.8) 46 (27.5)
Normal (≥80 to <150 ml/min) 31 (39.2) 37 (42.0) 68 (40.7)
Mild renal failure (>50 to <80 ml/min) 23 (29.1) 18 (20.5) 41 (24.6)
Moderate renal failure (>30 to ≤50 ml/min) 5 (6.3) 2 (2.3) 7 (4.2)
Severe renal failure (≤30 ml/min) 2 (2.5) 3 (3.4) 5 (3.0)
Failed antibiotic treatment, n (%)
N 55 68 123
No 45 (81.8) 58 (85.3) 103 (83.7)
Yes 10 (18.2) 10 (14.7) 20 (16.3)
Prior antibacterial therapy usage (hours), n (%)
N 79 88 167
<24 19 (24.1) 29 (33.0) 48 (28.7)
≥24 to <48 8 (10.1) 8 (9.1) 16 (9.6)
≥48 to ≤72 6 (7.6) 3 (3.4) 9 (5.4)
>72 46 (58.2) 48 (54.5) 94 (56.3)
Adjunctive therapy, n (%)
N 79 88 167
No 49 (62.0) 68 (77.3) 117 (70.1)
Yes
≤72 Hrs 23 (29.1) 15 (17.0) 38 (22.8)
>72 Hrs 7 (8.9) 5 (5.7) 12 (7.2)
Adjunctive aminoglycoside, n (%)
N 30 20 50
No 15 (50.0) 11 (55.0) 26 (52.0)
Yes
≤72 hrs 14 (46.7) 8 (40.0) 22 (44.0)
>72 hrs 1 (3.3) 1 (5.0) 2 (4.0)
Adjunctive vancomycin/linezolid, n (%)
N 30 20 50
No 9 (30.0) 6 (30.0) 15 (30.0)
Yes
≤72 hrs 16 (53.3) 11 (55.0) 27 (54.0)
>72 hrs 5 (16.7) 3 (15.0) 8 (16.0)
APACHE, Acute Physiology and Chronic Health Evaluation; CPIS, Clinical Pulmonary Infection Score; MITT, microbiological intention-to -treat; SOFA, Sequential
Organ Failure Assessment
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analyses for the MITT group (20.7% (19/92) doripenem,
16.7% (17/102) imipenem-cilastatin; 95% CI, -7.0% to
15.0%). Kaplan-Meier estimates are presented graphi-
cally for 28-day all-cause mortality for the ITT and
MITT populations (see Additional file 1). Figure 4
demonstrates that the Kaplan-Meier curves for the P.
aeruginosa subgroup are statistically, significantly differ-
ent over the treatment arms (nominal P-value = 0.040)
with an increased separation after completion of study
drug administration. Notably, no patient in the imipe-
nem arm with P. aeruginosa VAP died. In contrast,
mortality rates for patients with Acinetobacter spp. VAP
were lower for patients treated with doripenem (13.3%
(2/15) versus 30.0% (3/10); 95% CI: -49.9% to 16.5%).
Pharmacokinetics
The concentration data collected from 43 subjects trea-
ted with doripenem (between study Days 2 and 3) were
within the range of historical data in previously studied
critically ill patients administered doripenem 1 g for a
four-hour infusion. This data were utilized in a popula-
tion PK/PD analysis along with data from subjects with
Figure 2 Clinical cure rates at end of treatment by subgroup with 95% confidence intervals.
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VAP from previously conducted studies (manuscript
under preparation). Higher volumes of distribution were
observed in this study population, likely attributable to
high peripheral fluid volumes and the VAP disease state.
Despite this, doripenem levels were maintained at levels
sufficient to target pathogens isolated from subjects in
this study.
Discussion
The main reasons to consider the use of shorter courses
of antibiotic therapy for VAP are to minimize antibiotic-
related complications and to prevent the emergence of
antibiotic resistance. However, we demonstrated that
among patients with microbiologically confirmed VAP, a
fixed 7-day course of doripenem (one gram as a four-
hour infusion every eight hours) had non-significant
higher rates of clinical failure and mortality compared to
a fixed 10-day course of imipenem-cilastatin (one gram
as a one-hour infusion every eight hours). Moreover,
patients with VAP attributed to P. aeruginosa had a sta-
tistically greater risk of 28-day all-cause mortality when
treated with doripenem compared to imipenem-cilastatin
with an increased separation in the survival curves after
completion of study drug administration. This occurred
despite the use of prolonged infusions of doripenem
aimed at optimizing antibiotic concentration target
attainment above the MIC of bacterial pathogens during
the dosing interval suggesting that the shorter course of
doripenem administration played a role in this survival
difference [12,13].
Our findings are in contrast to some earlier studies
suggesting that shorter courses of antibiotic therapy for
VAP are safe and efficacious compared to longer treat-
ment courses. Ibrahim et al. showed that implementa-
tion of a clinical guideline for the treatment of VAP was
associated with greater administration of appropriate
initial antimicrobial treatment [14]. The duration of
antimicrobial treatment was also statistically shorter
Figure 3 Mean Clinical Pulmonary Infection Scores (CPIS) for the MITT treatment groups during antibiotic therapy. Error bars displayed
are based on the 95% confidence interval around the means. As there is significant dropout over time, as can be seen by the available sample
sizes at the bottom of the figure, the results have to be interpreted with caution. Nevertheless, the curves suggest that the patients’
improvement is similar for the two treatment arms up to Day 8 (the last day of active doripenem treatment), where after the decreasing trend is
continued for the subjects in the Imipenem-cilastatin arm (who receive active treatment up to Day 11), but remains stable for subjects in the
doripenem arm (who receive only placebo from Day 9 up to Day 11).
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with use of the guideline (8.6 ± 5.1 days versus 14.8 ±
8.1 days, P < 0.001) and second episodes of VAP
occurred statistically less often. In a subsequent study
the same group of investigators found that an antibiotic
discontinuation policy for clinically suspected VAP,
overseen by clinical pharmacists who were part of the
ICU team, could also significantly reduce the duration
of antibiotic therapy compared to therapy determined
by the treating physician teams (6.0 + 4.9 days versus
8.0 ± 5.6 days, P = 0.001) [15]. Secondary outcomes
including relapse of VAP, hospital mortality, and lengths
of stay were similar between groups, although the num-
ber of infections attributed to NLFGNB was small. Sev-
eral groups have also employed prediction tools like
CPIS and the biomarker procalcitonin to successfully
reduce the duration of antimicrobial therapy in patients
with VAP without adversely influencing patient out-
comes [16-18].
Table 3 Distribution of baseline qualifying Gram-negative pathogens
Doripenem Imipenem Total
(N = 79) (N = 88) (N = 167)
n (%) n (%) n (%)
Specific Gram-negative Pathogens 65 (82.3) 62 (70.5) 127 (76.0)
Pseudomonas aeruginosa 17 (21.5) 10 (11.4) 27 (16.2)
Monomicrobial* 8 (10.1) 6 (6.8) 14 (8.4)
Polymicrobial** 9 (11.4) 4 (4.5) 13 (7.8)
Acinetobacter spp. 15 (19.0) 10 (11.4) 25 (15.0)
Monomicrobial* 3 (3.8) 4 (4.5) 7 (4.2)
Polymicrobial** 12 (15.2) 6 (6.8) 18 (10.8)
Enterobacteriaceae 43 (54.4) 49 (55.7) 92 (55.1)
Monomicrobial* 14 (17.7) 14 (15.9) 28 (16.8)
Citrobacter koseri 1 (1.3) 0 1 (0.6)
Enterobacter aerogenes 0 1 (1.1) 1 (0.6)
Enterobacter cloacae 4 (5.1) 3 (3.4) 7 (4.2)
Escherichia coli 1 (1.3) 2 (2.3) 3 (1.8)
Klebsiella pneumoniae 5 (6.3) 4 (4.5) 9 (5.4)
Pantoea agglomerans 1 (1.3) 0 1 (0.6)
Proteus mirabilis 1 (1.3) 2 (2.3) 3 (1.8)
Serratia marcescens 1 (1.3) 2 (2.3) 3 (1.8)
Polymicrobial** 29 (36.7) 35 (39.8) 64 (38.3)
Citrobacter freundii 0 3 (3.4) 3 (1.8)
Enterobacter aerogenes 0 2 (2.3) 2 (1.2)
Enterobacter asburiae 1 (1.3) 0 1 (0.6)
Enterobacter cloacae 4 (5.1) 2 (2.3) 6 (3.6)
Enterobacter spp. (Not Speciated) 1 (1.3) 0 1 (0.6)
Escherichia coli 5 (6.3) 12 (13.6) 17 (10.2)
Klebsiella oxytoca 1 (1.3) 1 (1.1) 2 (1.2)
Klebsiella pneumoniae 14 (17.7) 16 (18.2) 30 (18.0)
Proteus mirabilis 3 (3.8) 3 (3.4) 6 (3.6)
Proteus vulgaris 1 (1.3) 1 (1.1) 2 (1.2)
Providencia spp. (Not Speciated) 0 1 (1.1) 1 (0.6)
Serratia marcescens 3 (3.8) 3 (3.4) 6 (3.6)
Pneumonia with MRS 7 (8.9) 4 (4.5) 11 (6.6)
Pseudomonas aeruginosa 2 (2.5) 1 (1.1) 3 (1.8)
Polymicrobial** 2 (2.5) 1 (1.1) 3 (1.8)
Acinetobacter spp. 2 (2.5) 1 (1.1) 3 (1.8)
Polymicrobial** 2 (2.5) 1 (1.1) 3 (1.8)
Enterobacteriaceae 4 (5.1) 2 (2.3) 6 (3.6)
Polymicrobial** 4 (5.1) 2 (2.3) 6 (3.6)
*: Monomicrobial pneumonia means a single qualifying pneumonia pathogen was isolated and no other pneumonia pathogen was isolated. **: Polymicrobial
pneumonia means at least one qualifying pneumonia pathogen was isolated and at least one other pneumonia pathogen was isolated. MRS, methicillin-resistant
Staphylococcus
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Table 4 Baseline clinical characteristics - P.
Doripenem Imipenem Total
(N = 17) (N = 10) (N = 27)
Sex, n (%)
N 17 10 27
Male 13 (76.5) 7 (70.0) 20 (74.1)
Female 4 (23.5) 3 (30.0) 7 (25.9)
Weight (kg)
N 17 10 27
Mean (SD) 74.0 (17.85) 68.3 (12.12) 71.9 (15.96)
Median 75.0 64.0 72.7
Range (45; 110) (52; 90) (45; 110)
Height (cm)
N 17 10 27
Mean (SD) 172.0 (10.11) 170.8 (7.74) 171.6 (9.17)
Median 170.0 171.0 170.0
Range (156; 190) (159; 180) (156; 190)
Age (Years)
N 17 10 27
Mean (SD) 57.5 (15.58) 50.9 (20.32) 55.1 (17.40)
Median 57.0 53.5 57.0
Range (33; 89) (25; 77) (25; 89)
Race, n (%)
N 17 10 27
White 16 (94.1) 7 (70.0) 23 (85.2)
Black or African American 1 (5.9) 2 (20.0) 3 (11.1)
Asian 0 1 (10.0) 1 (3.7)
Region, n (%)
N 17 10 27
Central and South America 5 (29.4) 3 (30.0) 8 (29.6)
Eastern Europe and Asia 5 (29.4) 4 (40.0) 9 (33.3)
Western Europe, North America, Australia 7 (41.2) 3 (30.0) 10 (37.0)
APACHE II score group, n (%)
N 17 10 27
≤15 6 (35.3) 3 (30.0) 9 (33.3)
16 to 19 5 (29.4) 3 (30.0) 8 (29.6)
≥20 6 (35.3) 4 (40.0) 10 (37.0)
CPIS, n (%)
N 17 10 27
<6 0 1 (10.0) 1 (3.7)
6 to 7 10 (58.8) 8 (80.0) 18 (66.7)
8 to 9 5 (29.4) 1 (10.0) 6 (22.2)
>9 2 (11.8) 0 2 (7.4)
SOFA score
N 10 4 14
Mean (SD) 5.4 (3.10) 4.0 (1.41) 5.0 (2.75)
Median 4.0 4.5 4.0
Range (1; 10) (2; 5) (1; 10)
Charlson Comorbidity Index
N 17 10 27
Mean (SD) 3.0 (2.26) 2.5 (1.96) 2.8 (2.13)
Median 3.0 3.0 3.0
Range (0; 9) (0; 5) (0; 9)
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However, a number of studies suggest that shorter
courses of antibiotic therapy for VAP may potentially be
less favorable in some circumstances, especially for
treatment of infections attributed to NLFGNB. Chastre
et al. showed that among patients with VAP, all of
whom received appropriate initial empiric antibiotic
therapy, comparable clinical effectiveness and outcomes
were obtained with 8- and 15-day treatment regimens
[5]. Yet, patients with VAP caused by NLFGNB, includ-
ing P. aeruginosa, receiving 8 days of treatment had a
higher pulmonary infection recurrence rate compared
with those receiving 15 days of treatment (40.6% versus
Table 4 Baseline clinical characteristics - P. (Continued)
PaO2/FiO2, n (%)
N 17 10 27
≤250 10 (58.8) 5 (50.0) 15 (55.6)
>250 7 (41.2) 5 (50.0) 12 (44.4)
Bacteremia, n (%)
N 17 10 27
No 16 (94.1) 10 (100) 26 (96.3)
Yes 1 (5.9) 0 1 (3.7)
Creatinine clearance, n (%)
N 17 10 27
Supra normal(≥150 ml/min) 5 (29.4) 4 (40.0) 9 (33.3)
Normal (≥80 to <150 ml/min) 5 (29.4) 2 (20.0) 7 (25.9)
Mild renal failure (>50 to <80 ml/min) 4 (23.5) 3 (30.0) 7 (25.9)
Moderate renal failure (>30 to ≤50 ml/min) 2 (11.8) 1 (10.0) 3 (11.1)
Severe renal failure (≤30 ml/min) 1 (5.9) 0 1 (3.7)
Failed antibiotic treatment, n (%)
N 11 8 19
No 8 (72.7) 6 (75.0) 14 (73.7)
Yes 3 (27.3) 2 (25.0) 5 (26.3)
Prior antibacterial therapy usage (hours), n (%)
N 17 10 27
<24 4 (23.5) 0 4 (14.8)
≥24 to <48 2 (11.8) 1 (10.0) 3 (11.1)
≥48 to ≤72 1 (5.9) 0 1 (3.7)
>72 10 (58.8) 9 (90.0) 19 (70.4)
Adjunctive therapy, n (%)
N 17 10 27
No 7 (41.2) 6 (60.0) 13 (48.1)
Yes
≤72 hrs 8 (47.1) 3 (30.0) 11 (40.7)
>72 hrs 2 (11.8) 1 (10.0) 3 (11.1)
Adjunctive aminoglycoside, n (%)
N 10 4 14
No 4 (40.0) 2 (50.0) 6 (42.9)
Yes
≤72 hrs 5 (50.0) 2 (50.0) 7 (50.0)
>72 hrs 1 (10.0) 0 1 (7.1)
Adjunctive vancomycin/linezolid, n (%)
N 10 4 14
No 5 (50.0) 1 (25.0) 6 (42.9)
Yes
≤72 hrs 4 (40.0) 2 (50.0) 6 (42.9)
>72 hrs 1 (10.0) 1 (25.0) 2 (14.3)
aeruginosa analysis set APACHE, Acute Physiology and Chronic Health Evaluation; CPIS, Clinical Pulmonary Infection Score; SOFA, Sequential Organ Failure
Assessment
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25.4%; 95% CI, 3.9% to 26.6%). Hedrick et al. retrospec-
tively evaluated 154 patients with VAP attributed to
NLFGNB where 27 patients were treated with three to
eight days (mean 6.4 + 0.3 days) of antibiotics and 127
received nine or more days (mean 17.1 + 0.7 days) of
therapy [19]. Although not statistically different, the
mortality rate was higher for patients receiving the
shorter treatment courses (22% versus 14%; P = 0.38).
Other investigators have demonstrated that longer
courses of antibiotic therapy (10 to 14 days) are typically
needed to successfully treat VAP attributed to MDR
Gram-negative bacteria, often due to the presence of
initial inappropriate antibiotic treatment [20,21].
Several potential explanations may have accounted for
our findings. The importance of adequate antimicrobial
dosing as a determinant of outcome has been demon-
strated in several randomized controlled trials per-
formed in critically ill patients with nosocomial
pneumonia [22-24]. Potentially, inadequately dosed anti-
biotics (ceftobiprole and tigecycline) were associated
with statistically greater treatment failures and mortality
compared to more optimally dosed comparators. Addi-
tionally, the results from two recent meta-analyses
examining prolonged infusion of b-lactam antibiotics
found that continuous infusion of b-lactam antibiotics
led to the same clinical results as similar or higher
dosed intermittent infusion antibiotic therapy [25,26].
However, in one of these meta-analyses, a trend towards
benefit among patients receiving intermittent infusion
antibiotics possibly explained by the use of higher anti-
biotic doses was observed [26]. The findings from a
recent study examining epithelial lining fluid (ELF) con-
centrations of doripenem in normal volunteers reported
the area under the curve ELF to plasma ratios was com-
parable to other carbapenems and supports further the
use of the 1 g dose versus a 500 mg dose administered
as a four-hour infusion to achieve higher doripenem
levels in the ELF [27].
A population PK analysis to characterize the PK of
doripenem in patients with VAP using data from sub-
jects treated with doripenem from this study and
patients with VAP from previous studies showed good
PK coverage above MICs in this study, including the
subjects with supranormal creatinine clearance. In addi-
tion, the population PK/PD analysis demonstrated no
association between clinical outcomes and the infecting
pathogen MICs within the PK dataset from this study.
Plasma levels of doripenem were collected between
study Days 2 and 3 so the ability to determine these
doripenem exposure-response relationships closer to the
time that the study endpoint was assessed was limited.
However, notably, for subjects in both treatment arms,
cure rates and mortality did not appear to increase with
increasing MIC of the pathogens, suggesting conditions
other than MIC and antibiotic dosing played a role in
outcome. Furthermore, the mean distribution of CPIS
values during antibiotic treatment for the first seven
days of the study was similar for the two treatment
groups (Figure 3), only separating after completion of
therapy in the doripenem arm. This finding also sug-
gests that the duration of antibiotic therapy and not the
antibiotics themselves contributed to the observed dif-
ferences in outcomes.
Another potential explanation for our findings is that
achievement of the targeted antibiotic concentration
goals took longer with the use of the prolonged infusion
Figure 4 Kaplan-Meier curves for the P. aeruginosa subgroup. (P = 0.040, Log-Rank Test).
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compared to the shorter infusions of the time-dependent
carbapenems [28,29]. This could result in a delay in
clearance of the infection that could adversely influence
outcomes. The authors of a recent systematic review
describing the pharmacokinetics of b-lactam antibiotics
in the critically ill found that b-lactam antibiotic half-life
and time above the MIC were virtually unpredictable,
especially in those with normal renal function [30].
Moreover, two recent studies found that creatinine clear-
ance appears to be an important predictor of sub-thera-
peutic b-lactam concentrations in critically ill patients
[31,32]. Administration of a loading dose of doripenem
might have improved concentration target attainment
potentially allowing for a shorter course of effective ther-
apy, even in the setting of increased drug clearance
[30,32].
This study has several important limitations. First, clin-
ical outcomes were assessed within 24 hours after admin-
istration of the last dose of blinded study drug. The
timing of this visit provided three days for patients in the
doripenem arm but less than 24 hours in the imipenem-
cilastatin arm to relapse. Had the clinical outcome assess-
ment been postponed to a few days later, additional
relapses may have been observed in the imipenem-cilas-
tatin arm. Second, premature closure of the study limited
the number of patients in the MITT group and patho-
gen-specific subgroups. Third, there were a large number
of study sites located in many countries which likely have
different treatment practices, introducing additional
variability. Fourth, enrollment occurred over the course
of three years and we cannot exclude temporal changes
in supportive care or other practices also having intro-
duced additional variability. Fifth, allowing pathogens
with MICs greater than 8 μg/mL may have influenced
our results, especially for the shorter course of therapy.
Sixth, there were numerically more cases of VAP attribu-
ted to P. aeruginosa, A. baumannii and MRSA in the
doripenem arm compared to the imipenem-cilastatin
arm and other imbalances in baseline characteristics
between treatment groups which may have contributed
to the study findings. Lastly, there may be additional
imbalances between the two study groups that could
have increased the severity of VAP (for example, corti-
costeroid therapy, chronic obstructive pulmonary dis-
ease) that were not included in our analysis.
Conclusions
In summary, we demonstrated that a fixed 7-day course
of doripenem was found to have non-significant higher
rates of clinical failure and mortality compared to a fixed
10-day course of imipenem-cilastatin and a statistically
greater mortality for the subgroup of VAP attributed to
P. aeruginosa. Given the increasing prevalence of VAP
caused by MDR Gram-negative bacteria, it is imperative
that optimal antimicrobial treatment strategies be
employed to optimize efficacy while minimizing the
emergence of further antibiotic resistance [33]. In coun-
tries where doripenem 500 mg one-hour and four-hour
infusions are approved to treat adults with nosocomial
pneumonia, including VAP, the usual treatment duration
is 7 to 14 days and should be guided by the severity of ill-
ness, infecting pathogen and the patients’ clinical
response with consideration given to treating patients
with VAP for more than 7 days to optimize clinical out-
come. Moreover, the European Medicines Agency (EMA)
has recently recommended that doripenem 1 g doses
administered every eight hours as four-hour infusions be
considered in patients with augmented renal clearance
(particularly those with creatinine clearance ≥150 ml/
min) and/or in infections due to non-fermenting Gram-
negative pathogens, such as P. aeruginosa and Acineto-
bacter spp. Moreover, the EMA highlighted that the
usual treatment duration for patients with nosocomial
pneumonia, including VAP, is 10 to 14 days and often in
the upper range for patients infected with NLFGNB [34].
Key messages
• A fixed 7-day course of doripenem was found to
have non-significant higher rates of clinical failure
and mortality compared to a fixed 10-day course of
imipenem-cilastatin for the treatment of VAP.
• VAP due to NLFGNB should be treated with anti-
biotic courses that are longer than seven days.
• The use of prolonged infusion antibiotic therapy
for VAP needs additional study to determine its rela-
tive efficacy compared to standard therapy.
Additional material
Additional file 1: A randomized trial of 7-day doripenem versus 10-
day imipenem-cilastatin for ventilator-associated pneumonia on-
line supplement. Provides additional methods section, results and the
IDMC charter.
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